OHOlivier Hartmann

Olivier Hartmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivier Hartmann has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A writing workshop for children with cancer

    by D Oppenheim, V Pittolo, C Gericot, J Grill, O Hartmann, S Dauchy

    We present and comment on several short texts written in a writing workshop by children and adolescents treated for cancer. In addition to the obvious themes, the patients communicate the intense elements of the experience they are going through, including fear of injections, fear of not being cured, revolt, hope and a feeling of unreality, and raise the question “Why?”. They are proud to express their feelings, thoughts and creativity, and relieved to be able show that they remain themselves. This can help them maintain or regain confidence in themselves and in the ability of their parents and medical staff to understand them. We consider their pleasure, their parents’ and caregivers’ reactions and the quality of their work as it relates to their age, academic level, cultural environment and cognitive capacities. These examples may help to inform physicians and nurses about how they perceive patients (children or adults) and their needs and abilities, and thereby improve the quality of the relationship.


  • Palliative treatment in neuroblastoma: Etoposide (VP16), an effective drug

    by D. Valteau-Couanet, D. De Pasquale, J. Chevalier, M. Dubrel, C. Dufour, G. Goma, O. Hartmann

    10037 Background: No further treatment of relapse after high-dose chemotherapy (HDC) and stem cell transplantation (SCT) has been described yet. Patients treated at our centre can undergo phase I-II studies or palliative treatments. We present herewith our experience on VP16 in relapsing or progressing patients after HDC and SCT. Methods: VP16 was administered orally at the dose of 100 mg/m2/day for 3 consecutive days for 3 consecutive weeks with a stop of one week between the courses. It continued until evidence of clinical progression. Patients who received 1 to 2 courses were considered non-responders, those who received 2–4 courses poor- responders and those who received more than 4 courses good-responders. Results: From 1985 to 2006, 69 patients were treated with oral VP16 which was first-line relapse chemotherapy in 46 patients, second-line in 19, and third-line in 4. They received a total of 342 courses with a median of 3 (1–21) courses. 28 patients (40.5%) were non-responders, 17 (24.7%) poor responders and 24 (34.8%) were good responders and received a median of 8.5 (7–21) courses. No significant toxicity were observed and this treatment allowed a good quality of life. The only factor displayed to have a significant impact on response and survival was the time to relapse. Number and percentages of good-responders were 0 (0%), 4 (23%), and 20 (50%) (P= .006) and median time from relapse to death was 2.4 mos, 5.1 mos, and 12.3 mos in patients who relapsed between 0–6 mos, 7–12 mos, and > 12 mos, respectively. Conclusions: Low-dose oral VP16 schedule should be considered as an effective palliative treatment. As time to relapse has been demonstrated to impact on response and survival, this should be taken into account for further studies evaluating new drugs. No significant financial relationships to disclose.

  • Sequential high-dose chemotherapy with autologous stem cell rescue for children with high-risk medulloblastoma and supratentorial primitive neuroectodermal tumours

    by C. Dufour, V. Minard-Colin, J. Grill, E. Benhamou, G. Goma, O. Hartmann, C. Kalifa, D. Valteau-Couanet

    10019 Background: Prognosis of high-risk meduloblastoma (HR MB) and supratentorial primitive neuroectodermal brain tumours (sPNET) is poor. In an attempt to improve outcome, we have developed strategies based on sequential high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) and radiotherapy for thirteen years. Patients and methods: Seventy-nine children (median age, 3.95 years) were treated with HDC/ASCT (59 HR MB; 20 sPNET). All patients received induction chemotherapy with one or two cycles of carboplatin-etoposide. Treatment strategy was modified with time and according to the age. Eighteen children were treated by two courses of high dose melphalan (100mg/m2) and one course of busulfan thiotepa combination (regimen 1). Two myeloablative courses of melphalan (100mg/m2) with ASCT were performed in twenty-one children (regimen 2). Nine patients were planned to receive two courses of high dose thiotepa (600mg/m2;) with ASCT (regimen 3). Thirty-one children received five sequential courses of chemotherapy followed by ASCT : melphalan (100 mg/m2) at day 43, cisplatin (100 mg/m2) at day 64, melphalan at day 85, cisplatin at day 106 and thiotepa (720 mg/m2) at day 127 (regimen 4). Treatment was completed by age-adapted craniospinal irradiation plus local boost in HR MB and age-adapted local irradiation only in sPNET. Results: Two hundred forty two cycles of high-dose chemotherapy with stem cell rescue were administered. At the end of chemotherapy, 6 pts were in CR in regimen 1, 8 CR in regimen 2, 3 CR in regimen 3 and 14 CR in regimen 4. The visceral toxicity of the regimen 1 was unacceptable with 3 toxic deaths secondary to multiorgan failure and 7 hepatic veno-occlusive disease. The toxicity was manageable in regimen 2, 3 and 4. Conclusion: Sequential high-dose chemotherapy improves survival rates in patients with HR MB and sPNET. This approach can be used to alleviate the use of craniospinal radiotherapy particularly in young children. No significant financial relationships to disclose.


  • La tumeur d'Ewing

    by M. Taylor, M. Guillon, V. Champion, M. Marcu, J.B. Arnoux, O. Hartmann


  • Open Access

    Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases

    by V Minard-Colin, C Kalifa, J-M Guinebretiere, L Brugieres, J Dubousset, J-L Habrand, G Vassal, O Hartmann

    We analysed the clinical features and outcome of young patients with non-Ewing's flat bone sarcoma treated during the era of contemporary chemotherapy. The characteristics and outcome of 25 patients (15 males and 10 females) with primary or radiation-related flat bone sarcoma treated in the Pediatrics Department at the Institut Gustave Roussy from 1981 to 1999 were reviewed. In all, 20 patients had osteosarcoma, four chondrosarcoma and one malignant fibrous histiocytoma. The age at diagnosis ranged from 2 to 23 years (median, 15 years). Nine tumours were located in the craniofacial bones, 11 in the pelvis and five in flat bones at other sites. Four patients had metastatic disease at diagnosis. Radiation-associated flat bone osteosarcoma was diagnosed in 10 out of 25 cases. The projected overall survival and event-free survival (EFS) rates at 5 years were 45.1 and 34.3% for all the 25 patients. The EFS rate of patients with second bone sarcoma was similar to that of patients with de novo flat bone sarcoma (P=0.1). The aim of treatment was curative for 24 patients, 23 of whom were treated with intensive chemotherapy regimens and 19 with surgery. Significant adverse prognostic factors on survival included incomplete surgical resection (P=0.001) and use of regimens without pre- and postoperative chemotherapy (P=0.007). Nine of the 25 patients were treated with pre- and postoperative chemotherapy and complete surgical resection. Among them, eight are alive with no disease. Radical surgical resection is the overriding prognostic factor for flat bone sarcomas in young patients. Nevertheless, our results suggest a more favourable outcome since the advent of intensive chemotherapy.


  • Open Access

    Neuroblastoma in adolescents

    by Nathalie Gaspar, Olivier Hartmann, Caroline Munzer, Christophe Bergeron, Frédéric Millot, Lucie Cousin‐Lafay, Annie Babin‐Boilletot, Pascale Blouin, Christine Pajot, Carole Coze

    BACKGROUND: Less than 5% of neuroblastomas are diagnosed in adolescent patients. Previous studies of patients who were treated with less intensive chemotherapy regimens relative to currently available regimens suggested that adolescents survived longer than younger children, and this finding was related to a lack of myc‐N amplification. Those reports prompted the authors to study a cohort of adolescent patients who had been included in more recent trials.METHODS: The authors investigated the presentation, treatment, and outcome in 28 adolescent patients who were enrolled in studies of the French Society of Pediatric Oncology during the period from 1987 to 1999 and who were older than age 10 years at the time they were diagnosed with neuroblastoma. The results were used to compare this subpopulation with a control group of children.RESULTS: None of the six patients with Stage I–II disease either developed recurrent disease or died. At 5 years, disease progression was high (progression‐free survival [PFS], 28%) for the 9 adolescents with Stage III disease, but so was survival (overall survival [OS], 86%). The 13 adolescent patients with metastatic neuroblastoma had very poor outcomes (PFS, 18%; OS, 27%). Despite intensive therapy, advanced neuroblastoma appeared to carry a poorer prognosis in adolescent patients compared with children, although patients with Stage III disease had a more indolent course. No difference was found between adolescent patients and children regarding the clinical presentation, treatment schedule, or doses and tolerance of chemotherapy. The incidence of elevated urinary catecholamine metabolite secretion was lower in adolescents compared with children.CONCLUSIONS: Adolescent patients with advanced neuroblastoma had less favorable outcomes compared with children, even if survival in adolescents with Stage III disease seemed longer. Cancer 2003;98:349–55. © 2003 American Cancer Society.DOI 10.1002/cncr.11521


  • Open Access

    Hepatic focal nodular hyperplasia in children previously treated for a solid tumor

    by Celine Icher‐De Bouyn, Jerome Leclere, Graziella Raimondo, Hubert Ducou le Pointe, Dominique Couanet, Dominique Valteau‐Couanet, Olivier Hartmann

    BACKGROUND: The detection of hepatic nodules, particularly in patients treated for a previous malignancy, raises a diagnostic dilemma. Focal nodular hyperplasia (FNH) of the liver is an uncommon, benign tumor in children and must be differentiated from malignant hepatic lesions. The etiology of FNH is obscure, and its pathogenesis is poorly understood. FNH may be a reaction to localized vascular abnormalities and circulatory disturbances. The goal of the current study was to identify risk factors for the occurrence of FNH in children who had received prior treatment for a malignant tumor.METHODS: The current retrospective study examined 14 cases of FNH in pediatric patients who previously had been treated for a malignancy. Diagnosis was based on clinical and radiologic findings and was proven histologically in four cases.RESULTS: FNH lesions were discovered by chance during routine examination in 78% of patients. The incidence of FNH was particularly high in the current series (0.45%) compared with the incidence in the general pediatric population. High doses of alkylating agents (e.g., busulfan or melphalan), venoocclusive disease, and liver radiotherapy may be responsible for injury to the vascular endothelium and subsequent localized circulatory disturbances. FNH is characterized by the absence of complications after its detection; therefore, only close follow‐up is recommended.CONCLUSIONS: FNH appears to be a late complication of an iatrogenic vascular disease in children with a history of malignancy. Cancer 2003;97:3107–13. © 2003 American Cancer Society.DOI 10.1002/cncr.11452


  • Affections pseudotumorales : dix ans d’expérience dans un service d’oncologie pédiatrique

    by G Raimondo, V Ridola, L Brugières, D Couanet, D Valteau-Couanet, J Grill, F Pein, O Hartmann

  • Open Access

    How do parents perceive high-dose chemotherapy and autologous stem cell transplantation for their children

    by D Oppenheim, D Valteau-Couanet, S Vasselon, O Hartmann

    Our objective was to understand the parents’ perception of children treated in an ASCT unit. Parents (40) of children and adolescents were interviewed by the department psychiatrist-psychoanalyst, over 9 months. They expressed great distress (22), considerable difficulty in assuming their parental role (with feelings of helplessness and guilt), and had distorted relations with the child whose behavior was unusual and incomprehensible (22). The relation with care providers, who should be ‘all-powerful’ and harmless, was ambivalent (15). They found it difficult to think or refused to do so, because their ‘thoughts are terrifying’, and they wanted to forget everything (11). The couple was going through a crisis (9). Temporal landmarks were disturbed (8); ASCT was experienced as a threatening discontinuity in the course of treatment (parents were unable to think of the past, the future, or the present); social landmarks were disturbed (6) with loss of social and professional relations. We concluded that parents may experience intense distress and disorientation. Trained to understand the parents’ and their children's thoughts and behavior, the medical team, which includes a psycho-oncologist, can better help them to understand and support the children, to strike a balance between their parental role and other responsibilities, and prevent conflicts.